Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2022–2027

MITGEST · Quality Control of the Mitochondrial Gene Expression System in Health and Disease

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2022-10-01 → 2027-01-31
Финансиране от ЕС
2 557 901 €
Участници
24
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Митохондриалната ДНК и нейните механизми за контрол се изследват, за да се разбере как се проявяват заболявания като рак и редки генетични състояния. Това помага за разработването на по-добри методи за диагностика и нови стратегии за лечение на тези заболявания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Quality Control of the Mitochondrial Gene Expression System in Health and Disease

The MITGEST doctoral network aims to improve our understanding of mitochondrial function and dysfunction, with a particular focus on mitochondrial DNA (mtDNA) and its gene expression. The main goal of the project is to address the challenges associated with mitochondrial dysfunction underlying a broad spectrum of human diseases, including rare diseases, aging-related conditions and cancer. By filling the gaps in understanding the pathophysiology of mitochondrial diseases, MITGEST intends to foster innovation in diagnostic and therapeutic strategies while training the next generation of scientists through a multidisciplinary programme. The main objectives of MITGEST are: 1) to explore the quality control mechanisms of mtDNA and its expression; 2) to develop innovative methods to study and treat mitochondrial abnormalities; 3) to identify biomarkers and treatment options for mitochondrial dysfunction. This comprehensive initiative combines scientific research with transferable skills training emphasizing collaboration between academia and industry to create a sustainable and impactful research environment. MITGEST will unite world-class academic excellence in mtDNA maintenance and expression with private sector expertise in nucleic acid chemistry and the development of mitochondrial therapeutics to address this urgent need. As the first research training programme in this field to take a fully integrated approach, our 11 doctoral candidates (DCs) will elucidate how mtDNA is maintained and expressed and support the development of new methods to analyse RNA and DNA metabolism in mitochondria. These advances will complement and facilitate/enhance innovative treatment strategies and experimental medicine studies designed to mitigate mitochondrial dysfunction in a range of human diseases. Our network builds on proven collaborations and establishes new partnerships to deliver intersectoral and multidisciplinary scientific and transferable skills training to our 11 PhD students to generate the next generation of highly-skilled scientists able to exploit the latest advances in mitochondrial biology and medicine.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Mitochondria produce most of the energy the body acquires through food, and are thus pivotal players in cellular metabolism. Central to mitochondrial biology is the DNA in the organelle (mtDNA): its maintenance, correct RNA processing, and efficient translation are all essential and must be coordinated to ensure proper mitochondrial function and cellular physiology. Defective maintenance or expression of mtDNA alters energy and nutrient metabolism, which are increasingly recognized to impact medical disciplines, ranging from hundreds of genetic disorders to neurodegeneration, immunology, transmissible disease, cancer and ageing. A deep understanding of the mitochondrial gene expression system and new methods are urgently needed to develop treatments for the full panoply of mitochondrial disorders that feature mtDNA perturbation.MITGEST will unite world-class academic excellence in mtDNA maintenance and expression with private sector expertise in nucleic acid chemistry and the development of mitochondrial therapeutics to address this urgent need. As the first research training programme in this field to take a fully integrated approach, our 10 doctoral candidates (DC) will elucidate how mtDNA is maintained and expressed and support the development of new methods to analyse RNA and DNA metabolism in mitochondria. These advances will complement and facilitate/enhance innovative treatment strategies and experimental medicine studies designed to mitigate mitochondrial dysfunction in a range of human diseases. Our network of 7 beneficiaries and 12 associated partners from 8 European countries and Israel builds on proven collaborations and establishes new partnerships to deliver intersectoral and multidisciplinary scientific and transferable skills training to our 11 PhD students to generate the next generation of highly-skilled scientists able to exploit the latest advances in mitochondrial biology and medicine.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз